| MeSH term | MeSH ID | Detail |
|---|---|---|
| Down Syndrome | D004314 | 18 associated lipids |
| Pregnancy Complications | D011248 | 19 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Cerebrovascular Disorders | D002561 | 25 associated lipids |
| Ascites | D001201 | 25 associated lipids |
| Endometriosis | D004715 | 29 associated lipids |
| Coronary Artery Disease | D003324 | 47 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Liver Cirrhosis | D008103 | 67 associated lipids |
2,3-dinor, 6-keto-PGF1alpha
2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha
NCBI Entrez Crosslinks
All references with 2,3-dinor, 6-keto-PGF1alpha
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mizugaki M et al. | Microdetermination of 2,3-dinor-6-ketoprostaglandin F1 alpha in human urine using gas chromatography-high-resolution selected-ion monitoring. | 1994 | J. Chromatogr. B, Biomed. Appl. | pmid:7952110 |
| Daniel VC et al. | Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry. | 1994 | J. Chromatogr. B, Biomed. Appl. | pmid:8205238 |
| Ylikorkala O et al. | Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. | 1987 | J. Clin. Endocrinol. Metab. | pmid:2960690 |
| Ylikorkala O et al. | Renal prostacyclin and thromboxane in normotensive and preeclamptic pregnant women and their infants. | 1986 | J. Clin. Endocrinol. Metab. | pmid:3536979 |
| Fitzgerald DJ et al. | Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. | 1988 | J. Clin. Invest. | pmid:3183064 |
| Dowd NP et al. | Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. | 2001 | J. Clin. Invest. | pmid:11518732 |
| Song WL et al. | Niacin and biosynthesis of PGDâ‚‚by platelet COX-1 in mice and humans. | 2012 | J. Clin. Invest. | pmid:22406532 |
| Neiman J et al. | Urinary excretion of 2, 3-dinor-6-keto prostaglandin F1 alpha and platelet thromboxane formation during ethanol withdrawal in alcoholics. | 1987 | J. Clin. Pathol. | pmid:3584500 |
| Kimblad PO et al. | Prostanoid release after lung transplantation. | 1996 | J. Heart Lung Transplant. | pmid:8913917 |
| Barden AE et al. | Does a predisposition to the metabolic syndrome sensitize women to develop pre-eclampsia? | 1999 | J. Hypertens. | pmid:10489109 |
| Rasmanis G et al. | Prostacyclin production in myocardial infarction in the acute phase and during follow-up. | 1991 | J. Intern. Med. | pmid:1997639 |
| Morrow JD et al. | Increased formation of thromboxane in vivo in humans with mastocytosis. | 1999 | J. Invest. Dermatol. | pmid:10417625 |
| Mastrogiannis DS et al. | Cocaine decreases urinary prostacyclin release in pregnancy: correlation with uterine and umbilical Doppler velocimetry. | 2003 | J. Matern. Fetal. Neonatal. Med. | pmid:15061316 |
| Kuehl PG et al. | Systemic production of prostacyclin and thromboxane A2 does not correlate with patency of the ductus arteriosus in very low birth weight infants. | 1986 | J. Pediatr. | pmid:3519915 |
| Brown NJ et al. | Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. | 1996 | J. Pharmacol. Exp. Ther. | pmid:8930174 |
| Catella-Lawson F et al. | Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. | 1999 | J. Pharmacol. Exp. Ther. | pmid:10215647 |
| Capone ML et al. | Human pharmacology of naproxen sodium. | 2007 | J. Pharmacol. Exp. Ther. | pmid:17473175 |
| Neiman J et al. | Effects of a small dose of ethanol and calcium carbimide-induced acetaldehyde intoxication on human platelet aggregation, associated thromboxane formation and urinary excretion of 2,3-dinor-6-keto prostaglandin F1 alpha. | 1987 | J. Toxicol. Clin. Toxicol. | pmid:3612897 |
| Lin JS et al. | The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence. | 1992 | J. Urol. | pmid:1635125 |
| Hashimoto K et al. | Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. | 2004 | J. Virol. | pmid:15367596 |